Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib Monotherapy or Combination in Advanced Solid Tumors
NCT05253053Phase 2Completed
- Sponsor
- TransThera Biosciences
- Start
- Apr 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tinengotinib in solid tumor (advanced stage), cholangiocarcinoma (CCA), biliary tract cancer (BTC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), sponsored by TransThera Biosciences. Started Apr 2022; status: completed.
02
Drugs
tinengotinib
03
Conditions
solid tumor (advanced stage)cholangiocarcinoma (CCA)biliary tract cancer (BTC)triple-negative breast cancer (TNBC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05253053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253053.